التفاصيل البيبلوغرافية
| العنوان: |
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. |
| المؤلفون: |
Mayer-Hamblett, Nicole, Clancy, John Paul, Jain, Raksha, Donaldson, Scott H, Fajac, Isabelle, Goss, Christopher H, Polineni, Deepika, Ratjen, Felix, Quon, Bradley S, Zemanick, Edith T, Bell, Scott C, Davies, Jane C, Jain, Manu, Konstan, Michael W, Kerper, Natanya R, LaRosa, Tré, Mall, Marcus A, McKone, Edward, Pearson, Kelsie, Pilewski, Joseph M |
| المصدر: |
Lancet Respiratory Medicine; Oct2023, Vol. 11 Issue 10, p932-944, 13p |
| مصطلحات موضوعية: |
CYSTIC fibrosis transmembrane conductance regulator, CYSTIC fibrosis, NEW trials, CLINICAL trials |
| مستخلص: |
The growing use of modulator therapies aimed at restoring cystic fibrosis transmembrane conductance regulator (CFTR) protein function in people with cystic fibrosis has fundamentally altered clinical trial strategies needed to advance new therapeutics across an orphan disease population that is now divided by CFTR modulator eligibility. The development of a robust pipeline of nucleic acid-based therapies (NABTs)—initially directed towards the estimated 10% of the cystic fibrosis population who are genetically ineligible for, or intolerant of, CFTR modulators—is dependent on the optimisation of restricted trial participant resources across multiple development programmes, a challenge that will preclude the use of gold standard placebo-controlled trials. Advancement of a full pipeline of symptomatic therapies across the entire cystic fibrosis population will be challenged by smaller effect sizes and uncertainty regarding their clinical importance in a growing modulator-treated population with more mild and stable pulmonary disease. In this Series paper, we aim to lay the foundation for clinical trial strategy and community partnership that must deviate from established and familiar precedent to advance the future pipeline of cystic fibrosis therapeutics. [ABSTRACT FROM AUTHOR] |
|
Copyright of Lancet Respiratory Medicine is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
